Search

Your search keyword '"Darras, Basil T."' showing total 948 results

Search Constraints

Start Over You searched for: Author "Darras, Basil T." Remove constraint Author: "Darras, Basil T."
948 results on '"Darras, Basil T."'

Search Results

52. 2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants

54. Developmental milestones in type I spinal muscular atrophy

56. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials

59. Contributors

62. Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes

63. 2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants

67. Additional file 1 of Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States

69. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

70. List of Contributors

72. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function

74. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

75. Contributors

77. A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial

78. Nusinersen for Patients With Spinal Muscular Atrophy: 1415 Doses via an Interdisciplinary Institutional Approach

79. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network

81. Natural history of infantile‐onset spinal muscular atrophy

83. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

85. Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States.

86. Diagnostic capabilities of nanopore long‐read sequencing in muscular dystrophy

87. Pooled Safety Data from the Risdiplam Clinical Trial Development Program (P18-5.001)

88. MANATEE: A Study of RO7204239 in Combination with Risdiplam Treatment in Pediatric Patients with SMA (P16-5.002)

89. FIREFISH Parts 1 and 2: 24-month Safety and Efficacy of Risdiplam in Type 1 SMA (S39.005)

91. Distribution of Weight, Stature and Growth Status in Children and Adolescents with Spinal Muscular Atrophy: An Observational Retrospective Study in the United States

92. Multicenter Consensus Approach to Evaluation of Neonatal Hypotonia in the Genomic Era: A Review

93. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

94. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

98. Contributors

100. Introduction

Catalog

Books, media, physical & digital resources